Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
PubMed PMID 40005999 2025 literature and patent review discussing proposed biological activities and the lack of sufficient comprehensive clinical evidence
doi: 10.3390/biomedicines10112697
Potential benefits of AOD-9604: Targeted fat loss Improved body composition Minimal hormonal effects Low incidence of systemic side effects AOD-9604 is generally viewed as a body-composition peptide rather than a major weight-loss medication
Complementary work has documented activation of the VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) pathway, involved in angiogenesis, along with upregulation of early growth response genes (Egr-1) and the FAK-paxillin transcription factor in studied endothelial cells
The tripeptide has been shown in cell culture and animal models to prolong the anagen phase, giving follicles more time to produce mature, pigmented hair shafts
The specialist will then craft each patients customized treatment plan, tailoring certain aspects to help maximize each benefit
